2328. Safety of MMR Vaccination in Multiple Myeloma Patients Receiving Maintenance Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation.
Session: Poster Abstract Session: Transplants: Infection Epidemiology and Outcome in Stem Cell Transplantation
Saturday, October 29, 2016
Room: Poster Hall
Posters
  • MMR vaccine MM poster upload.pdf (605.4 kB)
  • Background: The safety of the measles, mumps and rubella vaccine (MMR) in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic stem cell transplantation (auto-HSCT) is largely unknown. At our institution the MMR vaccine is typically given around 24 months post auto-HSCT provided patients are not on any immunosupression.

    Methods: We conducted a retrospective study of multiple myeloma patients seen at Dana-Farber Cancer Institute, Boston, MA between May 2007 and January 2014 who met the following criteria: received an auto-HSCT, were receiving lenalidomide, bortezomib or both after HSCT, and received the MMR vaccine. Adverse events were recorded until 42 days after vaccination.

    Results: 136 patients met the study criteria. The median age was 64 years (29-79), 56.6% were male. 123 (90.4%) of these patients were on lenalidomide maintenance, 7 (5.2%) were on bortezomib, and 6 (4.4%) were on both. The median time between transplant and vaccination was 25 months (18-39). Adverse events are listed in the table.
    AEs up to Day 42 n (%)
    Rash* 5 (3.7)
    on lenalidomide 4
    Fever 2 (1.5)
    on lenalidomide 2
    URI± 17 (12.5)
    on lenalidomide
    Hospitalization  up to day 42 0 (0)
    Death  up to day 42 0 (0)

    n= number of patients

    *non-specific rash: groin rash (2), urticarial rash with known prior history (1), dry patches of skin (1), rash not otherwise characterized (1).

    ±Upper respiratory tract infection

    Conclusion: In this small cohort of multiple myeloma patients on maintenance lenalidomide and or bortezomib after auto-HSCT, MMR vaccine administered around 24 months after auto-HSCT was safe and well tolerated.

    Alisha Pandit, BA1, Houry Leblebjian, Pharm D2, Sarah P. Hammond, MD3, Jacob Laubach, MD1,4, Paul G. Richardson, MD1,4, Lindsey R. Baden, MD5, Francisco M. Marty, MD, FIDSA6 and Nicolas C. Issa, MD5, (1)Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, (2)Pharmacy, Dana-Farber Cancer Institute, Boston, MA, (3)Infectious Diseases, Brigham and Women's Hospital, Boston, MA, (4)Harvard Medical School, Boston, MA, (5)Division of Infectious Diseases, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, (6)Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA

    Disclosures:

    A. Pandit, None

    H. Leblebjian, None

    S. P. Hammond, Merck: Investigator , Research support
    Ansun Biopharma: Investigator , Research support

    J. Laubach, None

    P. G. Richardson, None

    L. R. Baden, None

    F. M. Marty, Alexion: Scientific Advisor , Consulting fee
    Ansun: Investigator , Research support
    Astellas: Consultant and Investigator , Consulting fee and Research support
    Basilea: Conference speaker , Speaker honorarium
    Chimerix: Consultant and Investigator , Consulting fee and Research support
    Gilead: Consultant and Investigator , Consulting fee and Research support
    GlaxoSmithKline: Consultant and Investigator , Consulting fee and Research grant
    LFB, S.A.: Consultant , Consulting fee
    Merck: Consultant and Investigator , Consulting fee and Research support
    Shire: Consultant and Investigator , Consulting fee and Research support
    WHISCON: Investigator , Research support
    Pfizer: Course speaker , Speaker honorarium
    Fate Therapeutics: Scientific Advisor , Consulting fee

    N. C. Issa, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.